Computational insights into KRAS G12C inhibition: exploring possible repurposing of Azacitidine and Ribavirin

References

• Al-Hassany, H. A., Albu-Rghaif, A., & Naji, M. (2021). Tumor diagnosis by genetic markers protein P-53, p16, C-MYC, N-MYC, protein K-Ras, and gene her-2 Neu is this possible. Pakistan Journal of Medical and Health Sciences, 15(8), 2350–2354. https://doi.org/10.53350/pjmhs211582350
   Web of Science ®Google Scholar
• Azeem, M., Hanif, M., Mahmood, K., Siddique, F., Hashem, H. E., Aziz, M., Ameer, N., Abid, U., Latif, H., Ramzan, N., & Rawat, R. (2023). Design, synthesis, spectroscopic characterization, in-vitro antibacterial evaluation and in-silico analysis of polycaprolactone containing chitosan-quercetin microspheres. Journal of Biomolecular Structure & Dynamics, 41(15), 7084–7103. https://doi.org/10.1080/07391102.2022.2119602
   PubMed Web of Science ®Google Scholar
• Bekker, H., Berendsen, H., Dijkstra, E., Achterop, S., Vondrumen, R. V., Vanderspoel, D., Sijbers, A., Keegstra, H., & Renardus, M. (1993). Gromacs-a parallel computer for molecular-dynamics simulations [Paper presentation]. 4th International Conference on Computational Physics (PC 92). Prague, Czechoslovakia.
   Google Scholar
• Berendsen, H. J., van der Spoel, D., & van Drunen, R. (1995). GROMACS: A message-passing parallel molecular dynamics implementation. Computer Physics Communications, 91(1–3), 43–56. https://doi.org/10.1016/0010-4655(95)00042-E
   Web of Science ®Google Scholar
• Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020). Small-molecule inhibitors directly targeting KRAS as anticancer therapeutics. Journal of Medicinal Chemistry, 63(23), 14404–14424. https://doi.org/10.1021/acs.jmedchem.0c01312
   PubMed Web of Science ®Google Scholar
• Cicenas, J., Tamosaitis, L., Kvederaviciute, K., Tarvydas, R., Staniute, G., Kalyan, K., Meskinyte-Kausiliene, E., Stankevicius, V., & Valius, M. (2017). KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Medical Oncology (Northwood, London, England), 34(2), 26. https://doi.org/10.1007/s12032-016-0879-9
   PubMed Web of Science ®Google Scholar
• Devi, S., Rangra, N. K., Rawat, R., Alrobaian, M. M., Alam, A., Singh, R., & Singh, A. (2021). Anti-atherogenic effect of Nepitrin-7-O-glucoside: A flavonoid isolated from Nepeta hindostana via acting on PPAR–α receptor. Steroids, 165, 108770. https://doi.org/10.1016/j.steroids.2020.108770
   PubMed Web of Science ®Google Scholar
• Dhillon, S. (2023). Adagrasib: First approval. Drugs, 83(3), 275–285. https://doi.org/10.1007/s40265-023-01839-y
   PubMed Web of Science ®Google Scholar
• Di Pierro, M., Elber, R., & Leimkuhler, B. (2015). A stochastic algorithm for the isobaric–isothermal ensemble with Ewald summations for all long range forces. Journal of Chemical Theory and Computation, 11(12), 5624–5637. https://doi.org/10.1021/acs.jctc.5b00648
   PubMed Web of Science ®Google Scholar
• Elrakaybi, A., Ruess, D. A., Lübbert, M., Quante, M., & Becker, H. (2022). Epigenetics in pancreatic ductal adenocarcinoma: Impact on biology and utilization in diagnostics and treatment. Cancers, 14(23), 5926. https://doi.org/10.3390/cancers14235926
   PubMed Web of Science ®Google Scholar
• Ganesan, A., Coote, M. L., & Barakat, K. (2017). Molecular dynamics-driven drug discovery: Leaping forward with confidence. Drug Discovery Today, 22(2), 249–269. https://doi.org/10.1016/j.drudis.2016.11.001
   PubMed Web of Science ®Google Scholar
• Hess, B., Bekker, H., Berendsen, H., & Lincs, J. F. (1977). A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18, 1463–1472. https://doi.org/10.1002/(SICI)1096-987X(199709)18:12%3C1463::AID-JCC4%3E3.0.CO;2-H
   Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. https://doi.org/10.1016/0263-7855(96)00018-5
   PubMedGoogle Scholar
• Karachaliou, N., Mayo, C., Costa, C., Magrí, I., Gimenez-Capitan, A., Molina-Vila, M. A., & Rosell, R. (2013). KRAS mutations in lung cancer. Clinical Lung Cancer, 14(3), 205–214. https://doi.org/10.1016/j.cllc.2012.09.007
   PubMed Web of Science ®Google Scholar
• Kodaz, H., Kostek, O., Hacioglu, B. M., Erdogan, B., Kodaz, E. C., Hacibekiroglu, I., Turkmen, E., Uzunoglu, S., & Cicin, I. (2017). Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer. Breast Cancer, 7, 1–7. https://doi.org/10.14744/ejmo.2017.22931
   Google Scholar
• Kong, Y., Jiang, C., Wei, G., Sun, K., Wang, R., & Qiu, T. (2023). Small molecule inhibitors as therapeutic agents targeting oncogenic fusion proteins: Current status and clinical. Molecules (Basel, Switzerland), 28(12), 4672. https://doi.org/10.3390/molecules28124672
   PubMed Web of Science ®Google Scholar
• Kulkarni, A. M., Kumar, V., Parate, S., Lee, G., Yoon, S., & Lee, K. W. (2022). Identification of New KRAS G12D inhibitors through computer-aided drug discovery methods. International Journal of Molecular Sciences, 23(3), 1309. https://doi.org/10.3390/ijms23031309
   PubMed Web of Science ®Google Scholar
• Kumar, A., Kumar, B., & Bhatia, R. (2023). Design, synthesis, molecular docking, and biological evaluation of isatin-based fused heterocycles as epidermal growth factor receptor inhibitors. Assay and Drug Development Technologies, 21(5), 222–233. https://doi.org/10.1089/adt.2022.120
   PubMed Web of Science ®Google Scholar
• Luo, J. (2021). KRAS mutation in pancreatic cancer. Seminars in Oncology, 48(1), 10–18. https://doi.org/10.1053/j.seminoncol.2021.02.003
   PubMed Web of Science ®Google Scholar
• Mark, P., & Nilsson, L. (2001). Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. The Journal of Physical Chemistry A, 105(43), 9954–9960. https://doi.org/10.1021/jp003020w
   Web of Science ®Google Scholar
• Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H I., Al-Hallak, M. N., & Azmi, A. S. (2020). KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treatment Reviews, 84, 101974. https://doi.org/10.1016/j.ctrv.2020.101974
   PubMed Web of Science ®Google Scholar
• Ou, S. H I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Ou, S. H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., & Christensen, J. G. (2022). First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). Journal of Clinical Oncology, 40(23), 2530–2538. https://doi.org/10.1200/JCO.21.02752
   PubMed Web of Science ®Google Scholar
• Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.K. (2022). The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews. Clinical Oncology, 19(10), 637–655. https://doi.org/10.1038/s41571-022-00671-9
   PubMed Web of Science ®Google Scholar
• Rawat, R., Kant, K., Kumar, A., Bhati, K., & Verma, M. S. (2021). HeroMDAnalysis: An automagical tool for GROMACS-based molecular dynamics simulation analysis. Future Medicinal Chemistry, 13(5), 447–456. https://doi.org/10.4155/fmc-2020-0191
   PubMed Web of Science ®Google Scholar
• Ryan, M. B., & Corcoran, R. B. (2018). Therapeutic strategies to target RAS-mutant cancers. Nature Reviews. Clinical Oncology, 15(11), 709–720. https://doi.org/10.1038/s41571-018-0105-0
   PubMed Web of Science ®Google Scholar
• Sacher, A., Patel, M. R., Miller, W. H., Jr., Desai, J., Garralda, E., Bowyer, S., Kim, T. W., De Miguel, M., Falcon, A., Krebs, M. G., Lee, J., Cheng, M., Han, S. W., Shacham-Shmueli, E., Forster, M., Jerusalem, G., Massarelli, E., Paz-Ares Rodriguez, L., Prenen, H., … LoRusso, P. (2022). OA03. 04 phase IA study to evaluate GDC-6036 monotherapy in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation. Journal of Thoracic Oncology, 17(9), S8–S9. https://doi.org/10.1016/j.jtho.2022.07.023
   Web of Science ®Google Scholar
• Schmid, N., Eichenberger, A. P., Choutko, A., Riniker, S., Winger, M., Mark, A. E., & Van Gunsteren, W. F. (2011). Definition and testing of the GROMOS force-field versions 54A7 and 54B7. European Biophysics Journal, 40(7), 843–856. https://doi.org/10.1007/s00249-011-0700-9
   PubMed Web of Science ®Google Scholar
• Timar, J., & Kashofer, K. (2020). Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Reviews, 39(4), 1029–1038. https://doi.org/10.1007/s10555-020-09915-5
   PubMed Web of Science ®Google Scholar
• Tria, S. M., Burge, M. E., & Whitehall, V. L. (2023). The therapeutic landscape for KRAS-mutated colorectal cancers. Cancers, 15(8), 2375. https://doi.org/10.3390/cancers15082375
   PubMed Web of Science ®Google Scholar
• Valsangkar, N. P., Ingkakul, T., Correa-Gallego, C., Mino-Kenudson, M., Masia, R., Lillemoe, K. D., Fernández-del Castillo, C., Warshaw, A. L., Liss, A. S., & Thayer, S. P. (2015). Survival in ampullary cancer: Potential role of different KRAS mutations. Surgery, 157(2), 260–268. https://doi.org/10.1016/j.surg.2014.08.092
   PubMed Web of Science ®Google Scholar
• Van Aalten, D. M., Bywater, R., Findlay, J. B., Hendlich, M., Hooft, R. W., & Vriend, G. (1996). PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. Journal of Computer-Aided Molecular Design, 10(3), 255–262. https://doi.org/10.1007/BF00355047
   PubMed Web of Science ®Google Scholar
• Van Gunsteren, W. F., & Berendsen, H. J. (1988). A leap-frog algorithm for stochastic dynamics. Molecular Simulation, 1(3), 173–185. https://doi.org/10.1080/08927028808080941
   Web of Science ®Google Scholar
• Vaught, A. (1996). Graphing with Gnuplot and Xmgr: Two graphing packages available under linux. Linux Journal, 1996(28es), 7–es. https://doi.org/10.5555/326327.326334
   Google Scholar
• Wang, C., & Fakih, M. (2021). Targeting KRAS in colorectal cancer. Current Oncology Reports, 23(3), 28. https://doi.org/10.1007/s11912-021-01022-0
   PubMed Web of Science ®Google Scholar
• Wang, J., Martin-Romano, P., Cassier, P., Johnson, M., Haura, E., Lenox, L., Guo, Y., Bandyopadhyay, N., Russell, M., Shearin, E., Lauring, J., & Dahan, L. (2022). Phase I study of JNJ-74699157 in patients with advanced solid tumors harboring the KRAS G12C mutation. The Oncologist, 27(7), 536–e553. https://doi.org/10.1093/oncolo/oyab080
   PubMed Web of Science ®Google Scholar
• Yekeen, Abiodun, A., Durojaye, A. O., Idris, O. M., Muritala, F. H., & Arise, O. R. (2023). CHAPERONg: A tool for automated GROMACS-based molecular dynamics simulations and trajectory analyses. Computational and Structural Biotechnology Journal, 21, 4849–4858. https://doi.org/10.1016/j.csbj.2023.09.024
   PubMed Web of Science ®Google Scholar